|Articles|November 27, 2018
OmniComm’s TrialMaster® EDC Selected for Multi-Study Cancer Research
Advertisement
An international biopharmaceutical company has signed a multiyear agreement with OmniComm Systems, Inc. in which the company will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple research sites to test a cancer treatment.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Clarifying Ownership of IRT Data in Clinical Trials: Distinguishing Investigator-Controlled Data from Sponsor Operational Data
2
Nipocalimab Delivers Positive Phase IIb Results in JASMINE SLE Trial
3
Building More Representative Cancer Trial Populations
4
ACT Brief: Reframing Site Initiation Readiness, Operational Execution as Competitive Advantage, and a Historic Motion Sickness Approval
5